HCA

Business profile & competitive position

HCA Healthcare, Inc. is classified in the Healthcare sector under the Medical - Care Facilities industry. As of its most recent SEC filing, the company is one of the largest health care services operators in the United States, running 190 hospitals at December 31, 2025: 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals. The network also includes 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers spread across 19 states and England. Inpatient and outpatient medical/surgical care, emergency and diagnostic services, mental health treatment, physician practices, urgent/walk-in clinics, home health agencies, hospices, and rehabilitation services sit under the same umbrella.

The 2025 revenue base reached $75.6 billion, with 48.9% derived from managed care and other insurers and 14.9% from Medicare. On an operational level, an 8.8% net margin portrays a profitable, scaled acute-care platform. Yet the reported return on equity of -112.9% does not imply clinical or revenue failure; it reflects a highly leveraged balance sheet where equity is small relative to debt-financed assets such as hospitals, beds, and real estate. In hospital land, that capital structure is common, but it means ROE by itself is not a clean signal of competitive advantage. The more instructive read is that HCA generates decent profitability on a large revenue base of $75.6 billion, which is the hallmark of a national-scale operator with purchasing power and geographic density.

Financial posture

HCA currently carries a market capitalization of $99.3 billion and trades at a price-to-earnings ratio of 15.3. That P/E sits below the multiples often awarded to faster-growing or less capital-intensive health care names, and it tells you the market is pricing in persistent risks around reimbursement, labor expense, payer mix, and bad-debt exposure even as earnings hold up. The 8.8% net margin confirms the company is converting a meaningful slice of revenue into profit; the negative ROE simply underscores that total liabilities loom large relative to book equity.

Beta is 1.11, meaning the stock has historically moved slightly more than the broader market. The recent $458.51 price stands well above the 50-day exponential moving average of $423.68, while the relative strength index is at 69.3, just beneath the commonly cited 70 overbought threshold. Again, these are descriptive technical observations, not a directional call.

Strategic priorities & outlook

HCA's most recent 10-K filing outlines four concrete priorities. First, it intends to grow its presence in existing markets rather than pursue broad geographic expansion. Second, it aims to achieve industry-leading performance across clinical, operational, and satisfaction measures. Third, it emphasizes the recruitment and retention of physicians and other health care professionals to meet demand for high-quality services. Fourth, it plans to advance its digital and artificial intelligence capabilities.

Operationally, the company ended 2025 with 50,436 licensed beds in general acute care hospitals plus 714 beds in behavioral facilities. A structural theme in the filing is heavy concentration in Florida and Texas. That density creates local economies of scale, but it also means HCA is unusually exposed to regulatory changes, economic conditions, public health trends, and competitive dynamics specific to those two states.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, HCA is exposed to the standard macro forces that shape hospital economics. Reimbursement policy is at the top of the list: Medicare and Medicaid rate changes, federal deficit debates, and state-level Medicaid expansion or contraction can move revenue per patient. The industry is also labor-intensive, so wage pressure, nurse staffing ratios, and physician supply affect margins directly. Bad debt and uninsured patient volumes are another sensitivity, because hospitals absorb a meaningful share of uncollectible care.

Regulatory risk extends beyond payment. State certificate-of-need rules, facility licensing, antitrust review of large-scale acquisitions, and tort laws around medical malpractice all matter for this industry. Supply-chain disruptions for pharmaceuticals and medical devices can affect both costs and service availability. England operations add a modest currency dimension, though the vast majority of revenue is U.S. dollar-denominated. Interest rates matter too, because hospitals carry long-lived real estate and refinance debt periodically.

Recent developments

Recent headlines have been mixed. On October 12, 2026, Zacks.com published "Take the Zacks Approach to Beat the Markets: HF Sinclair, Accenture & FirstCash in Focus." On October 11, 2026, Seeking Alpha included HCA among its "Top 50 High-Quality Dividend Growth Stocks For October 2026." More cautionary were two near-identical investor alerts: on October 8, 2026, PR Newswire reported that Pomerantz Law Firm is investigating claims on behalf of investors of HCA Healthcare, Inc., and on October 6, 2026, GlobeNewswire carried the same alert. Both announcements noted an investigation into claims on behalf of investors; no allegations have been adjudicated, but the repeated alerts have appeared just ahead of the next earnings date.

Earnings behavior & post-earnings drift

HCA has beaten earnings estimates in each of the last eight reported quarters, a 100% beat rate, with an average surprise of 6.4%. The average 5-day price move after those reports has been +1.75%, classified as an "up" post-earnings drift. Context matters, though: the average is heavily influenced by earlier beats, while the most recent releases have been far narrower.

On July 24, 2026, HCA reported EPS of $7.59 against a $7.56 estimate, a 0.4% beat. The stock rose 1.94% the next day and 5.34% over the following five sessions. On April 24, 2026, EPS came in at $7.15 versus a $7.12 estimate, also a 0.4% surprise, with a 3.09% next-day gain that almost entirely faded to 0.15% over five days. The January 27, 2026 quarter was stronger on the beat, $8.01 versus $7.46 (7.4% surprise), yet the stock sold off 2.89% the next day and 1.31% over the following week. By contrast, the October 24, 2025 report delivered $6.96 versus $5.79, a 20.2% surprise, sending the shares up 4.66% the next day and 2.83% over five days.

The pattern suggests the market has become conditioned to beats; a narrow beat of 0.4% can feel underwhelming even if it extends the streak. The next report is scheduled for October 27, 2026, before the market open, with a consensus EPS estimate of $6.65. Given the 100% beat history, the market's real expectation may not be the published estimate alone; instead, it will likely focus on how much HCA exceeds that figure and what management says about volume, pricing, labor, and Florida-Texas trends.

For an institutional-grade picture beyond headline beats and P/E ratios, consider reviewing the full analyst verdict, which aggregates rating changes, target revisions, and sector-relative commentary.